Clinical Trial Update: Evaluate the Effect of ReSpace™ Hydrogel on Reducing Rectal Radiation Dose in Radiotherapy for Cervical Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating ReSpace™ Hydrogel to reduce rectal radiation dose during radiotherapy for cervical cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uterine Cervical Neoplasms

Drugs mentioned

• ReSpace™ Hydrogel

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Uterine Cervical Neoplasms | Phase 2 | Status: UNKNOWN